Moderna falls after STAT says large COVID-19 vaccine study delayed

A 30,000-patient trial of Moderna’s coronavirus vaccine candidate which was expected to start next week has been delayed, Damian Garde of STAT reports. Moderna is making changes to the trial plan, which has pushed back the expected start date of the Phase 3 study, Garde says, citing investigators. The investigators, who spoke on condition of anonymity, emphasized that protocol changes are common but said it’s not clear how long the start will be delayed, he added. Shares of Moderna are down 5% to $58.64 following the report. Following the STAT report, Moderna CEO Stephane Bancel told CNBC following that the trial is on track to start in July.